Partner Bayer pushes Ionis' antithrombotic drug into mid-stage development

[cafead]

via In 2015, when Ionis Pharmaceuticals carried the ill-fated name of Isis Pharmaceuticals, it granted Bayer the license to develop its programs targeting Factor XI — a clotting factor produced in the liver — for the treatment of clotting disorders. On Wednesday, the German drugmaker supported taking one of their experimental anti-thrombotic therapy’s into a Phase II trial, triggering a $10 million milestone payment for Ionis.

article source